Key result
Nicotinamide riboside is safe, well-tolerated, and boosts blood NAD+ by ~30 uM in HFrEF.
Why the study?
Mitochondrial dysfunction in HF is associated with altered intracellular NAD+ and NADH levels, and raising NAD+ with nicotinamide riboside may represent a novel HFrEF treatment whose safety and tolerability required evaluation.
Does high-dose oral nicotinamide riboside (1,000 mg twice daily) demonstrate safety and tolerability and increase whole blood NAD+ levels compared to placebo in patients with clinically stable stage C HFrEF?
RCT (n=30)
Double-blind
2:1 allocation ratio
No
Does high-dose oral nicotinamide riboside (1,000 mg twice daily) demonstrate safety and tolerability and increase whole blood NAD+ levels compared to placebo in patients with clinically stable stage C HFrEF?
Answers are grounded in this paper and cite their sources.
In the first randomized, placebo-controlled trial of nicotinamide riboside in patients with HFrEF, high-dose oral NR (1,000 mg twice daily) was safe, well-tolerated, and approximately doubled whole blood NAD+ levels, which correlated with improved PBMC mitochondrial respiration and reduced NLRP3 inflammatory gene expression.
The mitochondrial dysfunction characteristic of heart failure (HF) is associated with changes in intracellular nicotinamide adenine dinucleotide (NAD+) and NADH levels. Raising NAD+ levels with the NAD+ precursor, nicotinamide riboside (NR), may represent a novel HF treatment. In this 30-participant trial of patients with clinically stable HF with reduced ejection fraction, NR, at a dose of 1,000 mg twice daily, appeared to be safe and well tolerated, and approximately doubled whole blood NAD+ levels. Intraindividual NAD+ increases in response to NR correlated with increases in peripheral blood mononuclear cell basal (R2 = 0.413, P = 0.003) and maximal (R2 = 0.434, P = 0.002) respiration, and with decreased NLRP3 expression (R2 = 0.330, P = 0.020). (Nicotinamide Riboside in Systolic Heart Failure; NCT03423342)
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted an RCT in Clinically stable ACC/AHA stage C heart failure with reduced ejection fraction (HFrEF) (n=30). Nicotinamide riboside vs. Matching placebo was evaluated on Safety and tolerability (treatment-emergent adverse events and treatment compliance) (p=0.15). Nicotinamide riboside was safe, well-tolerated, and increased whole blood NAD+ levels in HFrEF.
Synapse has enriched 10 related papers. Consider them for comparative context: